文献速递心外重症与机械循环支持

肌营养不良儿童及年轻成人心室辅助装置的初始多中心经验:ACTION登记分析

Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: An ACTION registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2022-09-20

该研究分析了2012年9月至2020年9月间在ACTION中心为肌营养不良合并扩张型心肌病患者植入心室辅助装置(VAD)的结局。共12个中心为18例患者植入19台VAD,主要病种为抗肌萎缩蛋白病(66%),植入中位年龄17.2岁。1年和2年良好结局(移植或带装置存活)频率分别为84%和78%。作者认为VAD在肌营养不良患者中具有潜在效用,需进一步研究。

要点

  • 18例肌营养不良合并扩张型心肌病患者在12个中心共植入19台VAD。
  • 1年及2年良好结局(移植或带装置存活)频率分别为84%和78%。
  • 以决定或目的治疗植入的13例中,1年存活77%,2年存活69%。

核心结论

  • 本研究显示VAD疗法在肌营养不良患者中具有潜在效用。
  • 需要进一步研究以改善结局并更好地确定哪些患者可能从VAD疗法中获得最大生存和生活质量获益。

研究设计与样本

  • 多中心登记分析,纳入2012年9月至2020年9月在ACTION中心植入VAD的肌营养不良合并扩张型心肌病患者。
  • 共12个中心为18例患者植入19台VAD。

主要发现

  • 大多数患者为抗肌萎缩蛋白病(66%),植入时中位年龄17.2岁(范围11.7-29.5)。
  • 11例(61%)不能行走,6例(33%)在VAD前接受呼吸支持。
  • 5例(28%)以移植前桥接植入,其中4例存活至移植。
  • 以决定或目的治疗植入的13例中,1年存活77%,2年存活69%。
  • 1年和2年总体良好结局(移植或带装置存活)频率分别为84%和78%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以改善结局并更好地确定哪些患者可能从VAD疗法中获得最大生存和生活质量获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cardiac disease results in significant morbidity and mortality in patients with muscular dystrophy (MD). Single centers have reported their ventricular assist device (VAD) experience in specific MDs and in limited numbers. This study sought to describe the outcomes associated with VAD therapy in an unselected population across multiple centers. METHODS: We examined outcomes of patients with MD and dilated cardiomyopathy implanted with a VAD at Advanced Cardiac Therapies Improving Outcomes Network (ACTION) centers from 9/2012 to 9/2020. RESULTS: A total of 19 VADs were implanted in 18 patients across 12 sites. The majority of patients had dystrophinopathy (66%) and the median age at implant was 17.2 years (range 11.7-29.5). Eleven patients were non-ambulatory (61%) and 6 (33%) were on respiratory support pre-VAD. Five (28%) patients were implanted as a bridge to transplant, 4 of whom survived to transplant. Of 13 patients implanted as bridge to decision or destination therapy, 77% were alive at 1 year and 69% at 2 years. The overall frequencies of positive outcome (transplanted or alive on device) at 1 year and 2 years were 84% and 78%, respectively. Two patients suffered a stroke, 2 developed sepsis, 1 required tracheostomy, and 1 experienced severe right heart failure requiring right-sided VAD. CONCLUSIONS: This study demonstrates the potential utility of VAD therapies in patients with muscular dystrophy. Further research is needed to further improve outcomes and better determine which patients may benefit most from VAD therapy in terms of survival and quality of life.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Nandi D, Auerbach SR, Bansal N, et al. Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: An ACTION registry analysis. J Heart Lung Transplant. 2022. PMID: 36270923. doi:10.1016/j.healun.2022.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。